Patents Assigned to Intra-Cellular Therapies, Inc.
  • ORGANIC COMPOUNDS
    Publication number: 20220280517
    Abstract: The disclosure relates to methods of administering comprising administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment and/or prophylaxis of renal disorders, such as chronic kidney disease. Related compounds and methods of making are further defined.
    Type: Application
    Filed: August 21, 2020
    Publication date: September 8, 2022
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Robert E. DAVIS, Peng LI
  • Organic compounds
    Patent number: 11427587
    Abstract: The invention relates to particular prodrugs of substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: August 30, 2022
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Hailin Zheng, Robert Davis, Sharon Mates, Kimberly Vanover, Gretchen Snyder
  • Hydrochloric acid salt of (6bR,10aS)-3-methyl-2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxaline
    Patent number: 11407751
    Abstract: The present invention provides methods for the preparation of substituted heterocycle fused gamma-carbolines, such as Formula 2J, as shown below, intermediates useful in producing them and methods for producing such intermediates and such heterocycle fused gamma-carbolines, and as further defined herein:
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: August 9, 2022
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: John Charles Tomesch, Peng Li, Qiang Zhang, Andrew S. Thompson
  • Organic compounds
    Patent number: 11376249
    Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: July 5, 2022
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Wei Yao, Robert Davis, Sharon Mates, Kimberly Vanover, Gretchen Snyder
  • ORGANIC COMPOUNDS
    Publication number: 20220184240
    Abstract: The present invention relates to novel compounds having a capacity for PDE1 inhibition which may be used as tracers for use in diagnostic techniques, biomarkers for phosphodiesterase 1 (PDE1) in vivo, methods for treating and/or developing novel therapies for PDE1-associated conditions, and to methods of detection and treatment.
    Type: Application
    Filed: April 10, 2020
    Publication date: June 16, 2022
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Lawrence P. WENNOGLE, Robert DAVIS, Peng LI
  • Amorphous solid dispersions
    Patent number: 11331316
    Abstract: The disclosure provides new, stable, pharmaceutically acceptable amorphous solid dispersions of 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, together with methods of making and using them, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: May 17, 2022
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventor: Peng Li
  • NOVEL METHODS
    Publication number: 20220142932
    Abstract: The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.
    Type: Application
    Filed: January 24, 2022
    Publication date: May 12, 2022
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng LI, Robert DAVIS
  • NOVEL DEVICES
    Publication number: 20220125791
    Abstract: Disclosed herein are novel drug eluting contact lenses configured to release one or more compounds that inhibit phosphodiesterase 1 (PDE1). The PDE1 inhibitors may be administered as monotherapy or in combination with additional pharmaceutical agents in the treatment of an ophthalmic disease, disorder or injury. Related methods of use and treatment are also disclosed.
    Type: Application
    Filed: January 28, 2020
    Publication date: April 28, 2022
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Robert DAVIS, Allen A. FIENBERG
  • Amorphous solid dispersions
    Patent number: 11311536
    Abstract: The disclosure provides new, stable, pharmaceutically acceptable amorphous solid dispersions of 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, together with methods of making and using them, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: April 26, 2022
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventor: Peng Li
  • Uses
    Patent number: 11291666
    Abstract: The disclosure provides the administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment and prophylaxis of diseases or disorders characterized by inflammation, e.g., neuroinflammation, including methods of treatment and pharmaceutical compositions for use therein.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: April 5, 2022
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Gretchen Snyder, Lawrence P. Wennogle, Jennifer O'Brien, Joseph Hendrick
  • ORGANIC COMPOUNDS
    Publication number: 20220048910
    Abstract: Please add the following heading and paragraph on a separate sheet, after the claims: The invention relates to particular substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.
    Type: Application
    Filed: December 20, 2019
    Publication date: February 17, 2022
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng LI, Qiang ZHANG, Hailin ZHENG
  • ORGANIC COMPOUNDS
    Publication number: 20220008423
    Abstract: The invention relates to particular substituted deuterated heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.
    Type: Application
    Filed: July 19, 2021
    Publication date: January 13, 2022
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Wei YAO, Peng LI
  • NOVEL COMPOUNDS AND METHODS
    Publication number: 20210371421
    Abstract: The present invention relates to use of particular substituted heterocycle fused gamma-carbolines as described herein, in free, pharmaceutically acceptable salt or prodrug form, and pharmaceutical composition comprising the same optionally in combination with one or more agents, for the prophylaxis or treatment of one or more disorders associated with dementia, particularly behavioral or mood disturbances (e.g., agitation/aggression), psychosis, depression and sleep disturbances among others in patients suffering from dementia.
    Type: Application
    Filed: August 18, 2021
    Publication date: December 2, 2021
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon MATES, Robert DAVIS, Kimberly VANOVER, Lawrence WENNOGLE
  • NOVEL COMPOSITIONS AND METHODS
    Publication number: 20210361648
    Abstract: The disclosure provides new transmucosal and subcutaneous pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d2-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or comprising -(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d4-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, in free base, co-crystal or salt form, together with methods of making and using them.
    Type: Application
    Filed: June 3, 2021
    Publication date: November 25, 2021
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng LI, Wei YAO, Robert DAVIS
  • Combinations of PDE1 inhibitors and NEP inhibitors
    Patent number: 11166956
    Abstract: The invention relates to the combination of inhibitors of phosphodiesterase 1 (PDE1) and inhibitors of Neprilysin (NEP) useful for the treatment of certain cardiovascular diseases or related disorders, e.g., hypertension, congestive heart disease, and post-myocardial infarction. In another embodiment, the invention relates to the combination of inhibitors of PDE1 and inhibitors of NEP for the treatment of diseases or disorders characterized by disruption of or damage to various cGMP/PKG mediated pathways in the cardiovascular system (e.g., in cardiac tissue or in arterial smooth muscle).
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: November 9, 2021
    Assignee: Intra-Cellular Therapies, Inc.
    Inventors: Lawrence P. Wennogle, Peng Li
  • NOVEL USES
    Publication number: 20210338679
    Abstract: The disclosure provides the administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment and prophylaxis of diseases or disorders characterized by inflammation, including methods of treatment and pharmaceutical compositions for use therein.
    Type: Application
    Filed: September 25, 2019
    Publication date: November 4, 2021
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Gretchen SNYDER, Lawrence P. WENNOGLE, Jennifer O'BRIEN, Joseph HENDRICK
  • NOVEL METHODS
    Publication number: 20210322433
    Abstract: The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.
    Type: Application
    Filed: April 30, 2021
    Publication date: October 21, 2021
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Kimberly VANOVER, Peng LI, Sharon MATES, Robert DAVIS, Lawrence P. WENNOGLE
  • METHODS
    Publication number: 20210299124
    Abstract: The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.
    Type: Application
    Filed: May 27, 2021
    Publication date: September 30, 2021
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng LI, Robert DAVIS
  • 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms
    Patent number: RE48825
    Abstract: The present invention relates to toluenesulfonic acid addition salt crystals of 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3?,4?: 4,5]pyrrolo[1,2,3 -de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone, and methods of using such crystals as 5-hydroxytryptamine 2 receptor agonists and antagonists in treating disorders of the central nervous system.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: November 23, 2021
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: John Tomesch, Lawrence P. Wennogle
  • Methods and compositions for sleep disorders and other disorders
    Patent number: RE48839
    Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: December 7, 2021
    Assignee: Intra-Cellular Therapies, Inc
    Inventors: Sharon Mates, Allen Fienberg, Lawrence Wennogle